Evidence map›Paper›PMID 33968751›Full record

ArticleFrontiers in oncology2021

DDX54 Plays a Cancerous Role Through Activating P65 and AKT Signaling Pathway in Colorectal Cancer.

Yi Yu, Jing-Long Wang, Li-Li Meng, Chun-Ting Hu, Zhao-Wen Yan, Zhi-Ping He, Xiao-Qin Shi, Guo-Hui Fu, Li-Dong Zu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Proteome Analysis ofFrontiers in oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yi YuPathology Center, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
Jing-Long WangDepartment of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li-Li MengDepartment of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chun-Ting HuDepartment of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhao-Wen YanDepartment of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhi-Ping HeDepartment of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiao-Qin ShiPathology Center, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
Guo-Hui FuPathology Center, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
Li-Dong ZuDepartment of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Jiao Tong University · CNShanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most malignant cancers, and its incidence is still steadily increasing. The DDX RNA helicase family members have been found to play a role in various cancers; however, the role of DDX54 in colorectal cancer is still unclear and needed to be defined. Here, we found DDX54 was overexpressed in CRC tissues by the label-free mass spectrum, which was also verified in tissue microarray of colon cancer, as well as the CRC cell lines and TCGA database. High DDX54 level was correlated with tumor stage and distant metastasis, which always indicated a poor prognosis to the CRC patients. DDX54 could promote the proliferation and mobility of CRC cells through increasing the phosphorylation level p65 and AKT leading to the tumorigenesis. Here, we have preliminarily studied the function of DDX54 in CRC, which would improve our understanding of the underlying biology of CRC and provide the new insight that could be translated into novel therapeutic approaches.

Indexed as

AKTcolorectal cancerDDX54p65proteomics

Identifiers

PMID33968751
PMCPMC8097168
OpenAlexW3156621142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.